GLPwatch
In obesity or overweight without diabetes, orforglipron increased weight loss at 26 wk.
Ann Intern Med · 2023
Last updated 2026-05-28In a study of 272 adults with obesity or overweight without diabetes, those taking the GLP-1 drug orforglipron lost an average of 14.7% of their body weight after 26 weeks, compared to 2.8% in the placebo group. The study tested doses of 12 mg, 24 mg, and 36 mg, with higher doses generally leading to greater weight loss.
AI summary of the abstract below.
| Journal | Ann Intern Med, 2023 |
|---|---|
| Citations | 2 |
| Relative citation ratio | 0.19 |
| NIH percentile | 13 |
| Molecules | orforglipron |
| Conditions studied | Obesity |
Abstract
Wharton S, Blevins T, Connery L, et al; GZGI investigators. N Engl J Med. 2023;389:877-880. 37351564.
Verbatim abstract via PubMed 37782925 ↗
Related research
- Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
- Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
- Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.
- Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.
- The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron.
- Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: A systematic review and meta-analysis.